The trial aims to evaluate the safety, tolerability and pharmacokinetics of PRC-4016 in healthy volunteers.
Pronova CEO Morten Jurs said they believe PRC-4016 has an optimal profile to set new standards in the treatment of dyslipidemia, where there is a significant medical need for approaches capable of reducing triglycerides and non-HDL-C levels in the blood while raising levels of HDL-C.